Biote CORP

Biote Corp. announced a leadership transition with Bret Christensen stepping down as CEO, Robert Peterson appointed Interim CEO, and Marc Beer becoming Executive Chairman, while reaffirming 2026 guidance.

Biote Corp. announced the results of its 2026 annual meeting of stockholders, including the election of two Class I directors and the ratification of its independent auditor.

Biote Corp. announced first quarter 2026 financial results, reporting $44.9 million in revenue and a net income of $2.7 million, impacted by a voluntary product recall.

Biote Corp. released its investor presentation for April 2026, detailing 2025 financial results and providing a 2026 outlook, emphasizing growth in therapeutic wellness.

Biote Corp.'s subsidiary, Asteria Health, initiated a voluntary recall of specific hormone pellet lots due to potential metal particulate matter, expecting a $1.3M Q4 charge and $1.0M in 2026 costs.

Biote Corp. reported a 6.7% revenue decline to $48.0 million in Q3 2025, with net income falling to $9.2 million, while reiterating its full-year financial guidance.

Biote Corp. reported a significant decrease in revenue and net income for Q1 2026, impacted by a product recall, increased legal expenses, and a shift in revenue streams.

Biote Corp. reported a significant swing to net income for the nine months ended September 30, 2025, despite a decline in total revenue for both the quarter and year-to-date periods.

Biote Corp. reported a significant shift from net losses to net income and increased Adjusted EBITDA, driven by cost efficiencies and strategic supply chain management, despite a decline in core pellet procedure revenue.

biote Corp. reports a revenue increase and a return to net income profitability for Q1 2025, while navigating legal challenges and a CEO transition.

Biote Corp. announced its third quarter 2024 results, highlighting a 12.8% increase in revenue compared to the same period last year, driven by growth in product and service revenue.

Biote Corp. released its second quarter 2024 results, highlighting revenue growth in pellet procedures, offset by a decline in dietary supplement sales, and significant expenses related to legal settlements and acquisitions.

Biote Corp. reported a 2.5% revenue decrease and an 8.1% Adjusted EBITDA decline for 2025, alongside un-remediated internal control weaknesses and a product recall, despite a significant increase in net income driven by non-operating gains.

Biote Corp. announces its FY2024 financial results, highlighting revenue growth, a leadership transition, and strategic acquisitions aimed at strengthening its position in the hormone optimization market.

Biote Corp.'s annual 10-K filing details the company's authorized and outstanding stock, warrant terms, and various corporate governance provisions.

Biote Corp. Interim CEO Robert Peterson was granted 206,746 stock options as part of his compensation package.

Director Bret Christensen was granted 130,000 stock options in Biote Corp. with an exercise price of $2.34.

Executive Chairman Marc D. Beer was granted 114,157 employee stock options in Biote Corp. with an exercise price of $2.34.

Director Debra L. Morris reported the acquisition of Class A Common Stock and new equity awards in Biote Corp.

Director Stephen Mark Cone was granted 31,481 deferred settlement RSUs and 130,000 stock options by Biote Corp.

Director Dana Lynn Jacoby was granted 37,777 deferred settlement RSUs and 130,000 stock options by Biote Corp.

Biote Corp. has issued its proxy statement for the 2026 Annual Meeting of Stockholders to be held virtually on May 12, 2026.

Biote Corp. will hold its annual meeting virtually on May 13, 2025, to elect directors and ratify the appointment of its independent auditor.

Biote Corp. will hold its annual stockholders meeting on May 13, 2025, to elect directors and ratify the appointment of its independent accounting firm.

Biote Corp. will hold its annual meeting virtually on May 13, 2025, to elect directors and ratify the appointment of its independent auditor.

Biote Corp. will hold its annual stockholders meeting on May 21, 2024, to elect directors and ratify the appointment of its independent accounting firm.

Biote Corp. will hold its annual meeting of stockholders virtually on May 21, 2024, to elect directors and ratify the appointment of Deloitte & Touche LLP as its independent accounting firm.

A group of investors led by Richard Barrera, including Guines LLC and Roystone Management Holdings LLC, has disclosed a 14.0% beneficial ownership stake in biote Corp. following Barrera's appointment to the company's board of directors.

Bandera Partners LLC, along with Gregory Bylinsky and Jefferson Gramm, has reported beneficial ownership of 2,065,482 shares, representing 6.4% of biote Corp.'s Class A common stock.

An amendment to Schedule 13G reveals that Roystone Management Holdings LLC, RB Management GP LLC, Guines LLC, and Richard Barrera collectively maintain a 12.0% beneficial ownership in biote Corp.'s Class A common stock, with an internal shift in advisory responsibilities.